NCT04667988

JAK2 Mutation May Predict Response and Guide First Line Treatment in Rheumatoid Arthritis

Completed NA Last updated 16 December 2020

What this trial tests

NA trial testing JAK expression in Response Assessment in Newly Diagnosed RA Patients at 3rd Month Was Evaluated by DAS28 and ACR in Relation to JAK Expression in 76 participants. Completed in 1 May 2020.

Timeline

1 January 2019

Primary endpoint
1 April 2020

1 May 2020

Quick facts

Lead sponsor	Mansoura University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	single
Primary purpose	other
Enrollment	76
Start date	1 January 2019
Primary completion	1 April 2020
Estimated completion	1 May 2020
Sites	1 location across Egypt

Drugs / interventions tested

• JAK expression

Conditions studied

• Response Assessment in Newly Diagnosed RA Patients at 3rd Month Was Evaluated by DAS28 and ACR in Relation to JAK Expression — all drugs for Response Assessment in Newly Diagnosed RA Patients at 3rd Month Was Evaluated by DAS28 and ACR in Relation to JAK Expression →

Sponsor

Mansoura University

Who can join

Adults 18 to 80, any sex, with Response Assessment in Newly Diagnosed RA Patients at 3rd Month Was Evaluated by DAS28 and ACR in Relation to JAK Expression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study included 76 newly diagnosed RA patients and 50 matched controls. Basal JAK2 mutation was assessed by PCR in blood samples, TNF-α and IL 6 were measured by ELISA in serum of patients and controls. All patients started therapy with conventional synthetic DMARDs (including methotrexate). Response assessment at 3rd month was evaluated by DAS28 and ACR response criteria. JAK2 mutation was correlated with different clinical and laboratory parameters of patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.